# Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC

> **NCT06849167** · PHASE2 · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 63 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **RADIATION:** hypofractionated radiotherapy with immunotherapy

## Key facts

- **NCT ID:** NCT06849167
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2029-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06849167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06849167, "Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06849167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*